Children’s Heart Center is the first site in the United States to enroll a patient in a research study to test the pediatric use of a drug called Macitentan.
Research is just one of the ways we provide the very best care to those with congenital heart disease
Macitentan is a drug used to treat pulmonary arterial hypertension (PAH).
Dr. Rothman and Dr. Galindo are the Principal Investigators for Children’s Heart Center.
Patients between 2 and 18 years of age with a diagnosis of PAH may be eligible to enroll in the study which offers a $53.00 stipend per visit. Contact Shalethia at (702) 732-1290 for additional information and screening.